- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06756035
CT-95 i avancerad cancer associerad med mesotelinuttryck
Fas 1-studie av CT-95 i avancerad cancer associerad med mesotelinuttryck
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.
Studieöversikt
Status
Betingelser
- Kolorektal cancer
- Epitelial äggstockscancer
- Cholangiocarcinom Ej resektabel
- Lungadenokarcinom Metastaserande
- Malignt pleuralt mesoteliom, avancerad
- Cholangiocarcinoma Avancerat
- Pankreatisk Adenokarcinom Avancerat eller Metastaserande
- Mesotelinpositiva avancerade maligna solida tumörer
- Mesotelin-uttryckande avancerad cancer
- Malignt peritonealt mesoteliom, avancerad
- Mesotelin-uttryckande tumörer
Intervention / Behandling
Detaljerad beskrivning
Phase 1a Dose Escalation: Participants with ovarian epithelial tumors, primary peritoneal or fallopian tube cancer (PROC), epithelioid mesothelioma, lung adenocarcinoma, pancreatic adenocarcinoma, colorectal cancer, cholangiocarcinoma, and gastric/GEJ adenocarcinomas will be enrolled in one of approximately 9 dose escalation cohorts to assess the safety and tolerability of CT-95, as well as determine the maximum tolerated dose (MTD) or other recommended dose(s) for expansion (RDE[s]) for further dose expansion cohorts.
Participants will receive CT-95 as a single agent administered once weekly (QW) intravenously (IV) over a 4-week cycle.
Phase 1b Dose Expansion: The RDE(s) of CT-95 determined in Phase 1a will be evaluated in 2-4 indication-specific expansion cohorts of up to 20 subjects each (i.e. up to 80 participants total). Different indications, dose levels, and/or schedules may be explored. The expansion doses and/or dosing schedules for Phase 1b will be determined by Sponsor in conjunction with SRC based upon all available safety, PK, PD, biomarker, and preliminary efficacy data from Phase 1a.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80218
- Context Investigational Site
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- Context Investigational Site
-
-
Michigan
-
Grand Rapids, Michigan, Förenta staterna, 49546
- Context Investigational Site
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Context Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Context Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Context Investigational Site
-
-
Texas
-
San Antonio, Texas, Förenta staterna, 78229
- Context Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- ECOG 0 or 1
- Subjects with evaluable disease per RECIST 1.1 or mRECIST
- Subjects with adequate organ function.
- Subjects with advanced cancers associated with mesothelin expression
Exclusion Criteria:
- Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study.
- Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy
- Concurrent participation in another investigational clinical trial.
- Evidence of leptomeningeal disease
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: CT-95
Phase 1a: Dose Escalation - each dose cohort will assess toxicity 28 days following the first dose of CT95 anticipate a total of 8 dose cohorts. Phase 1b: Dose Expansion - approximately 80 participants will be evaluated in 2-4 indication-specific expansion cohorts. |
MSLN bispecific antibody to be administered according to the dose and schedule of the assigned cohort until documentation of disease progression (or confirmed disease progression), unacceptable toxicity, or participant/physician decision. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Determine the MTD or RD of CT-95 [Safety and Tolerability]
Tidsram: From date of first dose of CT-95 until 28 days following the first dose.
|
The frequency of dose-limiting toxicities (DLTs) will be analyzed along with safety and tolerability measures to determine the MTD or RD of CT-95. |
From date of first dose of CT-95 until 28 days following the first dose.
|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Tidsram: From date of first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.
|
The frequency and severity of adverse events, serious adverse events, and adverse events of special interest will be analyzed. |
From date of first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Evaluate Response Rates [Anti-tumor Activity]
Tidsram: At 8-week intervals from the time of the first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first
|
Overall response rates will be calculated using RECIST 1.1 (and mRECIST for patients with mesothelioma) for CT-95. |
At 8-week intervals from the time of the first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first
|
|
Evaluate Progression-free Survival [Anti-tumor Activity]
Tidsram: At 8-week intervals from the time of the first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.
|
PFS will be summarized using RECIST 1.1 (and mRECIST for patients with mesothelioma) for CT-95. |
At 8-week intervals from the time of the first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.
|
|
Evaluate Overall Survival [Survival]
Tidsram: From the time of the first dose of CT-95 until approximately two years post-first dose.
|
Overall survival will be summarized for CT-95. |
From the time of the first dose of CT-95 until approximately two years post-first dose.
|
|
Evaluate the Maximum Serum Concentration (Cmax) [Pharmacokinetics]
Tidsram: From date of first dose of CT-95 for 5 months or until treatment discontinuation, whichever comes first.
|
Serum concentrations of CT-95 analyzed as a function of time relative to dosing will be calculated. |
From date of first dose of CT-95 for 5 months or until treatment discontinuation, whichever comes first.
|
|
Evaluate the Area Under the Curve (AUC) [Pharmacokinetics]
Tidsram: From date of first dose of CT-95 for 5 months or treatment discontinuation, whichever comes first.
|
The AUC of CT-95 analyzed as a function of time relative to dosing will be calculated. |
From date of first dose of CT-95 for 5 months or treatment discontinuation, whichever comes first.
|
|
Evaluate Anti-Drug Antibodies [Immunogenicity]
Tidsram: From date of first dose of CT-95 for 5 months or until treatment discontinuation, whichever comes first.
|
Incidence and titer of ADAs will be evaluated. |
From date of first dose of CT-95 for 5 months or until treatment discontinuation, whichever comes first.
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Karen Chagin, MD, Context Therapeutics Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Sjukdomar i det endokrina systemet
- Patologiska processer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Tarmsjukdomar
- Luftvägssjukdomar
- Neoplasmer efter histologisk typ
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Genitala sjukdomar, kvinnor
- Lungsjukdomar
- Neoplasmer i endokrina körtel
- Neoplasmer, körtel och epitel
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Kolonsjukdomar
- Neoplastiska processer
- Lungneoplasmer
- Ovariella sjukdomar
- Adnexala sjukdomar
- Genitala neoplasmer, hona
- Gonadal sjukdomar
- Adenom
- Neoplasmer, mesotelial
- Pleurala neoplasmer
- Carcinom
- Ovariella neoplasmer
- Patologiska tillstånd, tecken och symtom
- Mesoteliom
- Karcinom, äggstocksepitel
- Mesoteliom, malignt
- Neoplasmer
- Kolorektala neoplasmer
- Neoplasma Metastas
Andra studie-ID-nummer
- CNTX-CT95-101
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .